British scientists say they're on the cusp of curing blindness with stem cell treatment
There is no cure for retinitis pigmentosa, an inherited condition that slowly constricts vision, but a British firm has reported early success with a procedure to repair a damaged retina. (Source: the Mail online | Health)
Source: the Mail online | Health - April 14, 2019 Category: Consumer Health News Source Type: news
Therapy could improve and prolong sight in those suffering vision loss
(University of California - Berkeley) Ganglion cells in the eye generate noise as the light-sensitive photoreceptors die in diseases such as retinitis pigmentosa. Now, UC Berkeley neurobiologists have found a drug and gene therapy that can tamp down the noise, improving sight in mice with RP. These therapies could potentially extend the period of useful vision in those with degenerative eye diseases, including, perhaps, age-related macular degeneration. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 13, 2019 Category: Biology Source Type: news
Second Sight Medical wins final CMS reimbursement nod for Argus II
Second Sight Medical (NSDQ:EYES) said today that the Centers for Medicare & Medicaid Services finalized the outpatient payment rate for its Argus II retinal prosthesis system for the coming year.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns to the brain, the Sylmar, Calif.-based company said.
CMS approved a Medicare hospital outpatient payment rate of $152,500 for the Argus II system and associated procedure, with the rate set to kick in next year.
“We ...
Source: Mass Device - November 8, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Regulatory/Compliance Second Sight Source Type: news
GenSight Biologics launches trial for gene therapy, eye device combo
GenSight Biologics (EPA:SIGHT) said today that the first person was treated in a first-in-man trial evaluating GenSight’s gene therapy candidate, GS030-DP, in combination with a wearable optronic visual stimulation device, GS030-MD.
Scientists are evaluating the drug-device combination in 18 people with retinitis pigmentosa.
Get the full story at our sister site, Drug Delivery Business News.
The post GenSight Biologics launches trial for gene therapy, eye device combo appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - October 26, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Clinical Trials Drug-Device Combinations Optical/Ophthalmic Pharmaceuticals Wall Street Beat gensightbiologics Source Type: news
Widespread errors in 'proofreading' cause inherited blindness
(Newcastle University) Research has shown that mistakes in 'proofreading' the genetic code of retinal cells is the cause of a form of inherited blindness, retinitis pigmentosa (RP) with splicing factor defects, which affects up to 2.5 million people worldwide. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - October 12, 2018 Category: International Medicine & Public Health Source Type: news
Bascom Palmer treats first US patient in Nightstar gene therapy
(University of Miami Miller School of Medicine) A Puerto Rican patient with X-linked retinitis pigmentosa (XLRP) is hoping to save his vision after an innovative gene therapy procedure at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine. On August 23, Julio Adorno Nieves, 23, became the first US patient to be given new genes for his inherited blinding condition in a worldwide Nightstar Therapeutics clinical trial. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 19, 2018 Category: International Medicine & Public Health Source Type: news
Researchers find potential new gene therapy for blinding disease
Scientists funded by NIH preserve vision in dogs with a disease similar to retinitis pigmentosa in humans. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - August 20, 2018 Category: American Health Source Type: news
Lessons from flies: genetic diversity impacts disease severity
(University of Utah Health) New research offers clues as to why some diseases are highly variable between individuals. The phenomenon is apparent in retinitis pigmentosa, a condition that causes the light-sensing cells in the eye to degenerate. By analyzing thousands of flies, scientists at University of Utah Health found that variation in a background gene, called Baldspot, can make a difference in severity of the disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 6, 2018 Category: International Medicine & Public Health Source Type: news
UCI researcher receives CIRM funding for stem cell-based retina therapy to treat blindness
(University of California - Irvine) California Institute of Regenerative Medicine funding to support continued development of a stem cell-based therapy for vision-robbing eye diseases, such as retinitis pigmentosa and macular degeneration. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - June 26, 2018 Category: Biology Source Type: news
Gene therapy that restores vision in dogs may help humans, too
(Michigan State University) A Michigan State University veterinary ophthalmologist has modified a gene therapy that reverses blindness in dogs that have a certain form of a disease known as progressive retinal atrophy, or PRA, and is now looking to advance the treatment for human use. Simon Petersen-Jones in the College of Veterinary Medicine has received a five-year, $8.2 million grant from the National Institutes of Health to further the therapy for people who have a type of retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 18, 2018 Category: International Medicine & Public Health Source Type: news
Genome surgery for eye disease moves closer to reality
(American Academy of Ophthalmology) Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 12, 2018 Category: International Medicine & Public Health Source Type: news
Strategy prevents blindness in mice with retinal degeneration
(Duke University Medical Center) New research published in Nature Communications outlines a strategy that in mouse models significantly delayed the onset of blindness from inherited retinal degeneration such as retinitis pigmentosa. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 1, 2018 Category: International Medicine & Public Health Source Type: news
Vitamin A Appears Helpful in Pediatric Retinitis Pigmentosa
MONDAY, April 2, 2018 -- For children with retinitis pigmentosa, vitamin A supplementation is associated with slower loss of cone electroretinogram amplitude, according to a study published online March 29 in JAMA Ophthalmology.
Eliot L. Berson,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 2, 2018 Category: Pharmaceuticals Source Type: news
Vitamin A Slows Progression of Retinitis Pigmentosa in Kids
(MedPage Today) -- Now the question is how (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - March 30, 2018 Category: Pediatrics Source Type: news
Medicare adds coverage in 3 states for Second Sight ’ s Argus II ‘ bionic eye ’
Second Sight Medical (NSDQ:EYES) said today that Medicare Administrative Contractor Palmetto GBA is now providing coverage for the Argus II retinal prosthesis system and its associated surgical procedures
The Sylmar, Calif.-based company said the approval expands coverage to Alabama, Georgia and Tennessee, bringing the total states covered for the device up to 31, as well as two territories and the District of Columbia.
The Argus II induces visual perception in blind patients with retinitis pigmentosa by stimulating of the retina’s remaining cells with electrical pulses, which allows for the perception of light patterns...
Source: Mass Device - March 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Optical/Ophthalmic Second Sight Source Type: news
